Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Conditions: HIV Infections; Tuberculosis Interventions: Drug: Bictegravir (BIC); Drug: Tenofovir alafenamide (TAF); Drug: Cabotegravir (CAB); Drug: Dolutegravir (DTG); Drug: Atazanavir/ritonavir (ATV/r); Drug: Darunavir/ritonavir (DRV/r); Drug: Lopinavir/ritonavir (LPV/r); Drug: Cobicistat; Drug: Ritonavir; Drug: First-Line TB Treatment; Drug: Second-Line TB Treatment; Drug: Doravirine (DOR) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); Gilead Sciences; ViiV Healthcare; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Child Development | Children | Clinical Trials | HIV AIDS | Infectious Diseases | Kaletra | Men | Norvir | Pediatrics | Pregnancy | Prezista | Research | Tuberculosis